|
Orthologous residues
|
|
Src (human): Y530‑p, Src (mouse): Y535‑p, Src iso2 (mouse): Y529‑p, Src (rat): Y530‑p, Src (chicken): Y527‑p
|
|
Characterization
|
|
Methods used to characterize site in vivo:
phospho-antibody, western blotting
|
|
Relevant cell lines - cell types - tissues:
293 (epithelial), 3T3 (fibroblast) [SHP-2 (mouse), homozygous knockout], Jurkat (T lymphocyte)
|
|
Cellular systems studied:
cell lines
|
|
Species studied:
human, mouse
|
|
Upstream Regulation
|
|
Potential in vivo enzymes for site:
|
|
Type
|
Enzyme
|
Evidence
|
Notes
|
|
KINASE
|
CSK (human)
|
pharmacological activator of upstream enzyme
|
|
|
|
Treatments, proteins and their effect on site modification:
|
|
Treatments
|
Referenced Treatments
|
Manipulated Protein
|
Referenced Protein
|
Effect
|
Notes
|
|
forskolin
|
|
|
|
increase
|
|
|
H-89
|
forskolin
|
|
|
inhibit treatment-induced increase
|
|
|
KT5720
|
forskolin
|
|
|
inhibit treatment-induced increase
|
|
|
prostaglandin E
|
|
|
|
increase
|
|
|
H-89
|
prostaglandin E
|
|
|
inhibit treatment-induced increase
|
|
|